Trial Profile
Phase Ib/II Trial of Stereotactic Body Radiotherapy (SBRT) in Cominbation With Immunotherapy Prior to Transoral Robotic Surgery (TORS) for Human Papillomavirus Positive (HPV+) Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2023 Status changed from active, no longer recruiting to discontinued due to slow accrual.
- 14 Nov 2022 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 14 Nov 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2023.